<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="105934">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01725308</url>
  </required_header>
  <id_info>
    <org_study_id>6949-CL-0021</org_study_id>
    <nct_id>NCT01725308</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy of FK949E in Bipolar Disorder Patients With Major Depressive Episodes</brief_title>
  <official_title>Phase II/III Study of FK949E — Placebo-controlled, Double-blind, Parallel-group Comparative Study and Open-label, Non-controlled Extension Study in Bipolar Disorder Patients With Major Depressive Episodes —</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In period I, the treatment effect of FK949E was compared with that of placebo in a blind
      manner in bipolar disorder patients with major depressive episodes. In period II, the
      long-term safety and efficacy of FK949E was evaluated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study consisted of two parts. In Treatment Period I, FK949E or placebo was administered
      orally in a blind manner to bipolar disorder patients with major depressive episodes, with
      the aim of evaluating the superiority of FK949 over placebo and the dose response of two
      doses of FK949E based on changes in Montgomery-Asberg Depression Rating Scale (MADRS) total
      score. In Treatment Period II, the long-term safety, efficacy and pharmacokinetics of FK949E
      was evaluated in patients completed the Treatment Period I. Results are reported for
      Treatment Period I.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline to End of Treatment Period I in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>The MADRS is a10-item scale to measure the severity of depressive episodes, where each item is rated on a scale from 0 to 6. The MADRS total score ranges from 0 to 60 with lower scores indicating less depressive symptoms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in MADRS Total Score</measure>
    <time_frame>Baseline and Weeks 1, 2, 3, 4, 6, 8</time_frame>
    <description>The MADRS is a10-item scale to measure the severity of depressive episodes, where each item is rated on a scale from 0 to 6. The MADRS total score ranges from 0 to 60 with lower scores indicating less depressive symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Hamilton Depression Rating Scale (HAM-D17) Total Score</measure>
    <time_frame>Baseline and Weeks 1, 2, 3, 4, 6, 8</time_frame>
    <description>The HAM-D17 is a clinician-rated 17-item scale for assessing the severity of depression symptoms. The scores for each item range from 0 to 4 or 0 to 2, where 0 represents no symptoms. The rating is based on the past 7 days prior to the time of assessment. The total score ranges from 0 to 52, where a higher score indicates a greater depressive state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Clinical Global Impression-Bipolar Disorder-Severity (CGI-BP-S): Mania</measure>
    <time_frame>Baseline and Weeks 1, 2, 3, 4, 6, 8</time_frame>
    <description>The CGI-BP-S is a scale which assesses a participant's severity of their overall bipolar illness, depression, and mania as assessed by the clinician using a scale from 1 (not ill) to 7 (very severely ill).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CGI-BP-S: Depression</measure>
    <time_frame>Baseline and Weeks 1, 2, 3, 4, 6, 8</time_frame>
    <description>The CGI-BP-S is a scale which assesses a participant's severity of their overall bipolar illness, depression, and mania as assessed by the clinician using a scale from with the scale from 1 (not ill) to 7 (very severely ill).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CGI-BP-S: Overall Bipolar Illness</measure>
    <time_frame>Baseline and Weeks 1, 2, 3, 4, 6, 8</time_frame>
    <description>The CGI-BP-S is a scale which assesses a participant's severity of their overall bipolar illness, depression, and mania as assessed by the clinician using a scale from with the scale from 1 (not ill) to 7 (very severely ill).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression-Bipolar Disorder-Change (CGI-BP-C): Mania</measure>
    <time_frame>Weeks 1, 2, 3, 4, 6, 8</time_frame>
    <description>The CGI-BP-C is a scale which assesses the degree of change or improvement from baseline for each of overall bipolar illness, depression and mania, by grading it using 8 grades, from 1 (very much improved) to 7 (very much worse) or 8 (not applicable). Grade 8 (not applicable) was regarded as a missing value for purposes of calculating the mean score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGI-BP-C: Depression</measure>
    <time_frame>Weeks 1, 2, 3, 4, 6, 8</time_frame>
    <description>The CGI-BP-C is a scale which assesses the degree of change or improvement from baseline for each of overall bipolar illness, depression and mania, by grading it using 8 grades, from 1 (very much improved) to 7 (very much worse) or 8 (not applicable). Grade 8 (not applicable) was regarded as a missing value for purposes of calculating the mean score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGI-BP-C: Overall Bipolar Illness</measure>
    <time_frame>Weeks 1, 2, 3, 4, 6, 8</time_frame>
    <description>The CGI-BP-C is a scale which assesses the degree of change or improvement from baseline for each of overall bipolar illness, depression and mania, by grading it using 8 grades, from 1 (very much improved) to 7 (very much worse) or 8 (not applicable). Grade 8 (not applicable) was regarded as a missing value for purposes of calculating the mean score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>up to 8 weeks</time_frame>
    <description>An adverse event (AE) is defined as any undesirable or unintended sign (including abnormal laboratory test values), symptom, or disease occurring while the study drug was administered, regardless of whether or not there was a causal relationship with the study drug. A serious AE is defined as a an event resulting in death, persistent or significant disability/incapacity or congenital anomaly or birth defect, was life-threatening, required or prolonged hospitalization or was considered medically important.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Drug Induced Extra-Pyramidal Symptoms Scale (DIEPSS): Total Score</measure>
    <time_frame>Baseline and Weeks 4, 8</time_frame>
    <description>The DIEPSS is a scale used to evaluate drug-induced extrapyramidal symptoms. DIEPSS is composed of 8 individual symptom parameters and a global assessment of severity, each rated on a 5-point scale, with lower scores indicating as &quot;normal.&quot; The DIEPSS total score ranges from 0 (none, normal) to 32 (severe), and excludes the global assessment of severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in DIEPSS: Parkinsonism</measure>
    <time_frame>Baseline and Weeks 4, 8</time_frame>
    <description>The DIEPSS is a scale used to evaluate drug-induced extrapyramidal symptoms. DIEPSS is composed of 8 individual symptom parameters and a global assessment of severity, each rated on a 5-point scale, with lower scores indicating as &quot;normal.&quot; Parkinsonism is a total of the gait disturbance, bradykinesia, salivation, muscle rigidity, and tremor scores and ranges from 0 (none, normal) to 20 (severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Young Mania Rating Scale (YMRS)</measure>
    <time_frame>Baseline and Weeks 1, 2, 3 4, 6, 8</time_frame>
    <description>The YMRS is a scale used to evaluate manic symptoms. The YMRS total score was the total assessment of assessed points for 11 items, ranges from 0 to 60 (each item is scored from either 0-4 or 0-8 by severity (0 = absent and 4/8 = displays mood/behavior to a greater degree). A lower score indicates &quot;Absent&quot; or &quot;Normal.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With an Affirmative Response to Columbia Suicide Severity Rating Scale (C-SSRS): Suicidal Ideation</measure>
    <time_frame>Weeks 4, 8</time_frame>
    <description>The C-SSRS is a scale for assessing risk for suicidal behavior and suicide ideation and was administered by the clinician. Affirmative or negative responses were provided to 5 items for suicide ideation (1. Wish to be dead; 2. Suicidal thoughts; 3. Suicidal thoughts with a method (no specific plan or intent to act); 4. Suicidal intent (without a specific plan); 5. Suicidal intent with specific plan. If participants responded with a negative response for questions 1 and 2, the remaining questions are skipped. If question 2 was responded to with a positive response, the remaining questions need to be asked.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With an Affirmative Response to C-SSRS: Suicidal Behaviors</measure>
    <time_frame>Weeks 4, 8</time_frame>
    <description>The C-SSRS is a scale for assessing risk for suicidal behavior and suicide ideation and was administered by the clinician. Affirmative or negative responses were provided to 7 items to suicidal behaviors (1. suicide attempt; 2. Self-injury without suicide intent; 3. discontinued suicide attempt; 4. interrupted suicide attempt; 5. preliminary action to suicide; 6. suicidal behavior; 7. completed suicide).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">431</enrollment>
  <condition>Bipolar Disorder</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants who received placebo once daily at bedtime for 8 weeks in Treatment Period I.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FK949E 150 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After 2 days of up-titration, participants received FK949E 150 mg once daily at bedtime for 8 weeks in Treatment Period I.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FK949E 300 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After 4 days of up-titration, participants received FK949E 300 mg once daily at bedtime for 8 weeks in Treatment Period I.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FK949E</intervention_name>
    <description>Taken by mouth (orally).</description>
    <arm_group_label>FK949E 300 mg</arm_group_label>
    <arm_group_label>FK949E 150 mg</arm_group_label>
    <other_name>quetiapine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Taken by mouth (orally).</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of bipolar I or II disorder as specified in the Diagnostic and Statistical
             Manual of Mental Disorders Ver. 4 Text Revision (DSM-IV-TR,) with a major depressive
             episode

          -  The Hamilton Depression Rating Scale (HAM-D17) total score of 20 points or more and
             HAM-D17 depressed mood score of 2 points or more

          -  Able to participate in the study with understanding of and compliance with subject
             requirements during the study in the investigator's or subinvestigator's opinion

        Exclusion Criteria:

          -  Concurrent or previous history of DSM-IV-TR Axis I disorders, except bipolar
             disorder, within the last 6 months before informed consent

          -  Concurrence of DSM-IV-TR Axis II disorder that is considered to greatly affect
             patient's current mental status

          -  The Young Mania Rating Scale (YMRS) total score of 13 points or more

          -  Nine or more mood episodes within the last 12 months before informed consent

          -  Lack of response to at least 6-week treatment with at least 2 antidepressants for the
             current major depressive episode in the investigator's or subinvestigator's opinion

          -  History of abuse or dependence of alcohol or substances other than caffeine and
             nicotine

          -  Treatment with a depot antipsychotic within the last 42 days before primary
             registration

          -  Unable to stop taking mood stabilizers (lithium carbonate and/or sodium valproate),
             lamotrigine, antipsychotics, or antidepressants from 7 days before secondary
             registration

          -  Unable to stop taking antiepileptics (except lamotrigine and sodium valproate),
             antianxiety agents, hypnotics, sedatives, psychostimulants, antiparkinsonian agents,
             cerebral ameliorators, antidementia agents, or anorectics, except those specified as
             conditionally-allowed concomitant drugs, after primary registration

          -  Electroconvulsive therapy within the last 76 days before primary registration

          -  The current major depressive episode persisting for more than 12 months or less than
             4 weeks before informed consent

          -  A possible need of psychotherapy during the study period (unless the therapy has been
             commenced at least 76 days before primary registration and been maintained on a fixed
             level at fixed frequency)

          -  Documented or suspected conditions such as renal failure, hepatic failure, serious
             cardiac disease, hepatitis B, hepatitis C, or acquired immunodeficiency syndrome
             (AIDS) (or to be a carrier of hepatitis B, hepatitis C, or AIDS)

          -  Concurrence of malignancy or history of cured malignancy within 5 years

          -  Concurrence of uncontrolled hypertension (defined as a systolic blood pressure of 180
             mmHg or more, or a diastolic blood pressure of 110 mmHg or more at primary
             registration) or unstable angina that may worsen with the study or may affect the
             study results based on the clinical judgment of the investigator or sub-investigator

          -  Concurrence of hypotension (defined as a systolic blood pressure of less than 100
             mmHg at primary registration) or orthostatic hypotension

          -  History of transient, idiopathic orthostatic hypotension, with or without pre-syncope
             symptoms or syncope, or a current condition susceptible to transient hypotension,
             such as dehydration and decreased blood volume

          -  Concurrent or previous history of cerebrovascular disease or transient ischemic
             attack (TIA)

          -  Abnormal laboratory or electrocardiographic findings considered clinically
             significant in the investigator's or subinvestigator's opinion (in reference to grade
             3 of the Adverse Drug Reactions Severity Grading Criteria [Notification No. 80 of the
             Safety Division, Pharmaceutical Affairs Bureau, Ministry of Health and Welfare dated
             29 June 1992])

          -  Participation in another clinical study or post-marketing study within the last 12
             weeks before informed consent

          -  History of quetiapine therapy during the current major depressive episode

          -  Pregnant or lactating women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site JP00030</name>
      <address>
        <city>Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00031</name>
      <address>
        <city>Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00052</name>
      <address>
        <city>Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00055</name>
      <address>
        <city>Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00072</name>
      <address>
        <city>Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00092</name>
      <address>
        <city>Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00003</name>
      <address>
        <city>Akita</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00008</name>
      <address>
        <city>Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00009</name>
      <address>
        <city>Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00002</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00037</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00038</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00039</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00040</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00041</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00058</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00082</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00083</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00091</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00094</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00095</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00096</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00097</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00098</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00004</name>
      <address>
        <city>Fukushima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00028</name>
      <address>
        <city>Gifu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00006</name>
      <address>
        <city>Gunma</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00007</name>
      <address>
        <city>Gunma</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00035</name>
      <address>
        <city>Hiroshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00056</name>
      <address>
        <city>Hiroshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00067</name>
      <address>
        <city>Hiroshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00001</name>
      <address>
        <city>Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00059</name>
      <address>
        <city>Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00061</name>
      <address>
        <city>Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00062</name>
      <address>
        <city>Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00068</name>
      <address>
        <city>Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00069</name>
      <address>
        <city>Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00073</name>
      <address>
        <city>Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00074</name>
      <address>
        <city>Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00076</name>
      <address>
        <city>Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00005</name>
      <address>
        <city>Ibaraki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00049</name>
      <address>
        <city>Kagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00021</name>
      <address>
        <city>Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00022</name>
      <address>
        <city>Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00023</name>
      <address>
        <city>Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00024</name>
      <address>
        <city>Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00025</name>
      <address>
        <city>Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00042</name>
      <address>
        <city>Kumamoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00050</name>
      <address>
        <city>Kumamoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00032</name>
      <address>
        <city>Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00084</name>
      <address>
        <city>Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00077</name>
      <address>
        <city>Miyagi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00027</name>
      <address>
        <city>Nagano</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00075</name>
      <address>
        <city>Nara</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00053</name>
      <address>
        <city>Oita</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00054</name>
      <address>
        <city>Okayama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00079</name>
      <address>
        <city>Okayama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00043</name>
      <address>
        <city>Okinawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00046</name>
      <address>
        <city>Okinawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00033</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00034</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00047</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00063</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00029</name>
      <address>
        <city>Shizuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00036</name>
      <address>
        <city>Tokushima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00010</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00011</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00012</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00013</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00014</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00015</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00016</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00017</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00018</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00019</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00020</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00045</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00048</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00051</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00057</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00060</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00064</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00065</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00066</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00070</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00071</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00078</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00081</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00085</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00086</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00087</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00088</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00089</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00090</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00093</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00099</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00044</name>
      <address>
        <city>Tottori</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP00026</name>
      <address>
        <city>Toyama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>February 17, 2017</lastchanged_date>
  <firstreceived_date>November 8, 2012</firstreceived_date>
  <firstreceived_results_date>December 16, 2016</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>FK949E</keyword>
  <keyword>Major depressive episode</keyword>
  <keyword>patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Japanese patients with bipolar I or bipolar II as specified in Diagnostic and Statistical Manual of Mental Disorders Ver. 4 Text Revision (DSM-IV-TR) whose most recent episode was diagnosed as a major depressive episode using the Mini-International Neuropsychiatric Interview (MINI) were recruited for this study.</recruitment_details>
      <pre_assignment_details>Assignment of participants to the FK949E 150 mg group was discontinued with implementation of Version 3.0 of the protocol. Results are reported for Treatment Period I.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment Period I: Placebo</title>
          <description>Participants who received placebo once daily at bedtime for 8 weeks in Treatment Period I.</description>
        </group>
        <group group_id="P2">
          <title>Treatment Period I: FK949E 150 mg</title>
          <description>After 2 days of up-titration, participants received FK949E 150 mg once daily at bedtime for 8 weeks in Treatment Period I.</description>
        </group>
        <group group_id="P3">
          <title>Treatment Period I: FK949E 300 mg</title>
          <description>After 4 days of up-titration, participants received FK949E 300 mg once daily at bedtime for 8 weeks in Treatment Period I.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="178"/>
                <participants group_id="P2" count="74"/>
                <participants group_id="P3" count="179"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="177"/>
                <participants group_id="P2" count="74"/>
                <participants group_id="P3" count="179"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="134"/>
                <participants group_id="P2" count="60"/>
                <participants group_id="P3" count="138"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="41"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Did Not Receive Drug</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="21"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Worsening of Underlying Disease</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Episode Change</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject Consent Withdrawal</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Deviations</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Miscellaneous</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full Analysis Set (FAS), which included participants who received at least one dose of study drug and had measurements taken for at least one efficacy endpoint after start of drug treatment in Treatment Period I.</population>
      <group_list>
        <group group_id="B1">
          <title>Treatment Period I: Placebo</title>
          <description>Participants who received placebo once daily at bedtime for 8 weeks in Treatment Period I.</description>
        </group>
        <group group_id="B2">
          <title>Treatment Period I: FK949E 150 mg</title>
          <description>Participants who received FK949E 150 mg once daily at bedtime for 8 weeks in Treatment Period I.</description>
        </group>
        <group group_id="B3">
          <title>Treatment Period I: FK949E 300 mg</title>
          <description>Participants who received FK949E 300 mg once daily at bedtime for 8 weeks in Treatment Period I.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="177"/>
            <count group_id="B2" value="74"/>
            <count group_id="B3" value="179"/>
            <count group_id="B4" value="430"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.8" spread="11.0"/>
                    <measurement group_id="B2" value="39.2" spread="10.2"/>
                    <measurement group_id="B3" value="38.1" spread="11.2"/>
                    <measurement group_id="B4" value="38.6" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="101"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="93"/>
                    <measurement group_id="B4" value="231"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="86"/>
                    <measurement group_id="B4" value="199"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total Montgomery-Åsberg Depression Rating Scale (MADRS) score</title>
          <description>The MADRS is a10-item scale to measure the severity of depressive episodes, where each item is rated on a scale from 0 to 6. The MADRS total score ranges from 0 to 60 with lower scores indicating less depressive symptoms.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.8" spread="6.4"/>
                    <measurement group_id="B2" value="30.2" spread="6.8"/>
                    <measurement group_id="B3" value="30.9" spread="6.9"/>
                    <measurement group_id="B4" value="30.7" spread="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total Hamilton Depression Rating Scale (HAM-D17) Score</title>
          <description>The HAM-D17 is a clinician-rated 17-item scale for assessing the severity of depression symptoms. The scores for each item range from 0 to 4 or 0 to 2, where 0 represents no symptoms. The rating is based on the past 7 days prior to the time of assessment. The total score ranges from 0 to 52, where a higher score indicates a greater depressive state.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.1" spread="2.8"/>
                    <measurement group_id="B2" value="23.3" spread="3.4"/>
                    <measurement group_id="B3" value="23.0" spread="3.0"/>
                    <measurement group_id="B4" value="23.1" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to End of Treatment Period I in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score</title>
        <description>The MADRS is a10-item scale to measure the severity of depressive episodes, where each item is rated on a scale from 0 to 6. The MADRS total score ranges from 0 to 60 with lower scores indicating less depressive symptoms.</description>
        <time_frame>Baseline and Week 8</time_frame>
        <population>FAS. Last observation carried forward (LOCF) imputation for end of Treatment Period I was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Period I: Placebo</title>
            <description>Participants who received placebo once daily at bedtime for 8 weeks in Treatment Period I.</description>
          </group>
          <group group_id="O2">
            <title>Treatment Period I: FK949E 150 mg</title>
            <description>After 2 days of up-titration, participants received FK949E 150 mg once daily at bedtime for 8 weeks in Treatment Period I.</description>
          </group>
          <group group_id="O3">
            <title>Treatment Period I: FK949E 300 mg</title>
            <description>After 4 days of up-titration, participants received FK949E 300 mg once daily at bedtime for 8 weeks in Treatment Period I.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to End of Treatment Period I in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score</title>
          <description>The MADRS is a10-item scale to measure the severity of depressive episodes, where each item is rated on a scale from 0 to 6. The MADRS total score ranges from 0 to 60 with lower scores indicating less depressive symptoms.</description>
          <population>FAS. Last observation carried forward (LOCF) imputation for end of Treatment Period I was used.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="177"/>
                <count group_id="O2" value="74"/>
                <count group_id="O3" value="179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.1" spread="10.9"/>
                    <measurement group_id="O2" value="-14.4" spread="11.4"/>
                    <measurement group_id="O3" value="-12.6" spread="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>An analysis of covariance (ANCOVA) using a model where the total MADRS score at baseline is a covariate and the treatment group and bipolar disorder diagnosis (Type I/ II) are fixed effects.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.034</p_value>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>-2.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.7</ci_lower_limit>
            <ci_upper_limit>-0.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in MADRS Total Score</title>
        <description>The MADRS is a10-item scale to measure the severity of depressive episodes, where each item is rated on a scale from 0 to 6. The MADRS total score ranges from 0 to 60 with lower scores indicating less depressive symptoms.</description>
        <time_frame>Baseline and Weeks 1, 2, 3, 4, 6, 8</time_frame>
        <population>FAS; LOCF imputation was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Period I: Placebo</title>
            <description>Participants who received placebo once daily at bedtime for 8 weeks in Treatment Period I.</description>
          </group>
          <group group_id="O2">
            <title>Treatment Period I: FK949E 150 mg</title>
            <description>After 2 days of up-titration, participants received FK949E 150 mg once daily at bedtime for 8 weeks in Treatment Period I.</description>
          </group>
          <group group_id="O3">
            <title>Treatment Period I: FK949E 300 mg</title>
            <description>After 4 days of up-titration, participants received FK949E 300 mg once daily at bedtime for 8 weeks in Treatment Period I.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in MADRS Total Score</title>
          <description>The MADRS is a10-item scale to measure the severity of depressive episodes, where each item is rated on a scale from 0 to 6. The MADRS total score ranges from 0 to 60 with lower scores indicating less depressive symptoms.</description>
          <population>FAS; LOCF imputation was used.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="177"/>
                <count group_id="O2" value="74"/>
                <count group_id="O3" value="179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.5" spread="5.4"/>
                    <measurement group_id="O2" value="-6.4" spread="8.1"/>
                    <measurement group_id="O3" value="-5.1" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.1" spread="7.0"/>
                    <measurement group_id="O2" value="-10.0" spread="8.9"/>
                    <measurement group_id="O3" value="-8.3" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.1" spread="8.8"/>
                    <measurement group_id="O2" value="-11.6" spread="9.9"/>
                    <measurement group_id="O3" value="-9.9" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.5" spread="9.1"/>
                    <measurement group_id="O2" value="-12.5" spread="10.8"/>
                    <measurement group_id="O3" value="-11.8" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.2" spread="10.1"/>
                    <measurement group_id="O2" value="-14.5" spread="11.0"/>
                    <measurement group_id="O3" value="-12.2" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.1" spread="10.9"/>
                    <measurement group_id="O2" value="-14.4" spread="11.4"/>
                    <measurement group_id="O3" value="-12.6" spread="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Hamilton Depression Rating Scale (HAM-D17) Total Score</title>
        <description>The HAM-D17 is a clinician-rated 17-item scale for assessing the severity of depression symptoms. The scores for each item range from 0 to 4 or 0 to 2, where 0 represents no symptoms. The rating is based on the past 7 days prior to the time of assessment. The total score ranges from 0 to 52, where a higher score indicates a greater depressive state.</description>
        <time_frame>Baseline and Weeks 1, 2, 3, 4, 6, 8</time_frame>
        <population>FAS; LOCF imputation method was used for all time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Period I: Placebo</title>
            <description>Participants who received placebo once daily at bedtime for 8 weeks in Treatment Period I.</description>
          </group>
          <group group_id="O2">
            <title>Treatment Period I: FK949E 150 mg</title>
            <description>After 2 days of up-titration, participants received FK949E 150 mg once daily at bedtime for 8 weeks in Treatment Period I.</description>
          </group>
          <group group_id="O3">
            <title>Treatment Period I: FK949E 300 mg</title>
            <description>After 4 days of up-titration, participants received FK949E 300 mg once daily at bedtime for 8 weeks in Treatment Period I.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hamilton Depression Rating Scale (HAM-D17) Total Score</title>
          <description>The HAM-D17 is a clinician-rated 17-item scale for assessing the severity of depression symptoms. The scores for each item range from 0 to 4 or 0 to 2, where 0 represents no symptoms. The rating is based on the past 7 days prior to the time of assessment. The total score ranges from 0 to 52, where a higher score indicates a greater depressive state.</description>
          <population>FAS; LOCF imputation method was used for all time points.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="177"/>
                <count group_id="O2" value="74"/>
                <count group_id="O3" value="179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.4" spread="4.2"/>
                    <measurement group_id="O2" value="-5.9" spread="5.1"/>
                    <measurement group_id="O3" value="-4.5" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.1" spread="5.4"/>
                    <measurement group_id="O2" value="-8.7" spread="5.8"/>
                    <measurement group_id="O3" value="-7.0" spread="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.6" spread="6.5"/>
                    <measurement group_id="O2" value="-10.0" spread="6.2"/>
                    <measurement group_id="O3" value="-7.9" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.3" spread="6.7"/>
                    <measurement group_id="O2" value="-10.9" spread="6.6"/>
                    <measurement group_id="O3" value="-9.2" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.7" spread="7.3"/>
                    <measurement group_id="O2" value="-11.9" spread="7.1"/>
                    <measurement group_id="O3" value="-9.6" spread="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.4" spread="7.6"/>
                    <measurement group_id="O2" value="-11.9" spread="7.4"/>
                    <measurement group_id="O3" value="-10.1" spread="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At End of Treatment Period I/Week 8: An analysis of covariance (ANCOVA) using a model where the total HAM-D17 score at baseline is a covariate and the treatment group and bipolar disorder diagnosis (Type I/II) are fixed effects.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.033</p_value>
            <method>ANCOVA</method>
            <param_type>Least squares mean difference</param_type>
            <param_value>-1.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.3</ci_lower_limit>
            <ci_upper_limit>-0.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Clinical Global Impression-Bipolar Disorder-Severity (CGI-BP-S): Mania</title>
        <description>The CGI-BP-S is a scale which assesses a participant's severity of their overall bipolar illness, depression, and mania as assessed by the clinician using a scale from 1 (not ill) to 7 (very severely ill).</description>
        <time_frame>Baseline and Weeks 1, 2, 3, 4, 6, 8</time_frame>
        <population>FAS; LOCF imputation method was used for all time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Period I: Placebo</title>
            <description>Participants who received placebo once daily at bedtime for 8 weeks in Treatment Period I.</description>
          </group>
          <group group_id="O2">
            <title>Treatment Period I: FK949E 150 mg</title>
            <description>After 2 days of up-titration, participants received FK949E 150 mg once daily at bedtime for 8 weeks in Treatment Period I.</description>
          </group>
          <group group_id="O3">
            <title>Treatment Period I: FK949E 300 mg</title>
            <description>After 4 days of up-titration, participants received FK949E 300 mg once daily at bedtime for 8 weeks in Treatment Period I.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Clinical Global Impression-Bipolar Disorder-Severity (CGI-BP-S): Mania</title>
          <description>The CGI-BP-S is a scale which assesses a participant's severity of their overall bipolar illness, depression, and mania as assessed by the clinician using a scale from 1 (not ill) to 7 (very severely ill).</description>
          <population>FAS; LOCF imputation method was used for all time points.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="177"/>
                <count group_id="O2" value="74"/>
                <count group_id="O3" value="179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0" spread="0.2"/>
                    <measurement group_id="O2" value="0.0" spread="0.2"/>
                    <measurement group_id="O3" value="0.0" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0" spread="0.2"/>
                    <measurement group_id="O2" value="-0.0" spread="0.2"/>
                    <measurement group_id="O3" value="0.0" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.2"/>
                    <measurement group_id="O2" value="-0.0" spread="0.2"/>
                    <measurement group_id="O3" value="0.0" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.2"/>
                    <measurement group_id="O2" value="-0.0" spread="0.4"/>
                    <measurement group_id="O3" value="0.0" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.3"/>
                    <measurement group_id="O2" value="-0.1" spread="0.2"/>
                    <measurement group_id="O3" value="0.0" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.3"/>
                    <measurement group_id="O2" value="-0.1" spread="0.4"/>
                    <measurement group_id="O3" value="0.0" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CGI-BP-S: Depression</title>
        <description>The CGI-BP-S is a scale which assesses a participant's severity of their overall bipolar illness, depression, and mania as assessed by the clinician using a scale from with the scale from 1 (not ill) to 7 (very severely ill).</description>
        <time_frame>Baseline and Weeks 1, 2, 3, 4, 6, 8</time_frame>
        <population>FAS; LOCF imputation method was used for all time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Period I: Placebo</title>
            <description>Participants who received placebo once daily at bedtime for 8 weeks in Treatment Period I.</description>
          </group>
          <group group_id="O2">
            <title>Treatment Period I: FK949E 150 mg</title>
            <description>After 2 days of up-titration, participants received FK949E 150 mg once daily at bedtime for 8 weeks in Treatment Period I.</description>
          </group>
          <group group_id="O3">
            <title>Treatment Period I: FK949E 300 mg</title>
            <description>After 4 days of up-titration, participants received FK949E 300 mg once daily at bedtime for 8 weeks in Treatment Period I.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CGI-BP-S: Depression</title>
          <description>The CGI-BP-S is a scale which assesses a participant's severity of their overall bipolar illness, depression, and mania as assessed by the clinician using a scale from with the scale from 1 (not ill) to 7 (very severely ill).</description>
          <population>FAS; LOCF imputation method was used for all time points.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="177"/>
                <count group_id="O2" value="74"/>
                <count group_id="O3" value="179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="0.7"/>
                    <measurement group_id="O2" value="-0.5" spread="0.8"/>
                    <measurement group_id="O3" value="-0.4" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="0.9"/>
                    <measurement group_id="O2" value="-0.8" spread="1.0"/>
                    <measurement group_id="O3" value="-0.7" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="1.1"/>
                    <measurement group_id="O2" value="-1.0" spread="1.1"/>
                    <measurement group_id="O3" value="-0.9" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="1.1"/>
                    <measurement group_id="O2" value="-1.2" spread="1.2"/>
                    <measurement group_id="O3" value="-1.1" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="1.2"/>
                    <measurement group_id="O2" value="-1.3" spread="1.2"/>
                    <measurement group_id="O3" value="-1.1" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="1.4"/>
                    <measurement group_id="O2" value="-1.4" spread="1.3"/>
                    <measurement group_id="O3" value="-1.2" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CGI-BP-S: Overall Bipolar Illness</title>
        <description>The CGI-BP-S is a scale which assesses a participant's severity of their overall bipolar illness, depression, and mania as assessed by the clinician using a scale from with the scale from 1 (not ill) to 7 (very severely ill).</description>
        <time_frame>Baseline and Weeks 1, 2, 3, 4, 6, 8</time_frame>
        <population>FAS; LOCF imputation method was used for all time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Period I: Placebo</title>
            <description>Participants who received placebo once daily at bedtime for 8 weeks in Treatment Period I.</description>
          </group>
          <group group_id="O2">
            <title>Treatment Period I: FK949E 150 mg</title>
            <description>After 2 days of up-titration, participants received FK949E 150 mg once daily at bedtime for 8 weeks in Treatment Period I.</description>
          </group>
          <group group_id="O3">
            <title>Treatment Period I: FK949E 300 mg</title>
            <description>After 4 days of up-titration, participants received FK949E 300 mg once daily at bedtime for 8 weeks in Treatment Period I.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CGI-BP-S: Overall Bipolar Illness</title>
          <description>The CGI-BP-S is a scale which assesses a participant's severity of their overall bipolar illness, depression, and mania as assessed by the clinician using a scale from with the scale from 1 (not ill) to 7 (very severely ill).</description>
          <population>FAS; LOCF imputation method was used for all time points.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="177"/>
                <count group_id="O2" value="74"/>
                <count group_id="O3" value="179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="0.7"/>
                    <measurement group_id="O2" value="-0.4" spread="0.8"/>
                    <measurement group_id="O3" value="-0.4" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="0.9"/>
                    <measurement group_id="O2" value="-0.7" spread="1.0"/>
                    <measurement group_id="O3" value="-0.7" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="1.0"/>
                    <measurement group_id="O2" value="-0.9" spread="1.1"/>
                    <measurement group_id="O3" value="-0.9" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="1.1"/>
                    <measurement group_id="O2" value="-1.1" spread="1.1"/>
                    <measurement group_id="O3" value="-1.1" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="1.2"/>
                    <measurement group_id="O2" value="-1.2" spread="1.2"/>
                    <measurement group_id="O3" value="-1.1" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="1.3"/>
                    <measurement group_id="O2" value="-1.4" spread="1.3"/>
                    <measurement group_id="O3" value="-1.2" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Global Impression-Bipolar Disorder-Change (CGI-BP-C): Mania</title>
        <description>The CGI-BP-C is a scale which assesses the degree of change or improvement from baseline for each of overall bipolar illness, depression and mania, by grading it using 8 grades, from 1 (very much improved) to 7 (very much worse) or 8 (not applicable). Grade 8 (not applicable) was regarded as a missing value for purposes of calculating the mean score.</description>
        <time_frame>Weeks 1, 2, 3, 4, 6, 8</time_frame>
        <population>FAS; LOCF imputation method was used for all time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Period I: Placebo</title>
            <description>Participants who received placebo once daily at bedtime for 8 weeks in Treatment Period I.</description>
          </group>
          <group group_id="O2">
            <title>Treatment Period I: FK949E 150 mg</title>
            <description>After 2 days of up-titration, participants received FK949E 150 mg once daily at bedtime for 8 weeks in Treatment Period I.</description>
          </group>
          <group group_id="O3">
            <title>Treatment Period I: FK949E 300 mg</title>
            <description>After 4 days of up-titration, participants received FK949E 300 mg once daily at bedtime for 8 weeks in Treatment Period I.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Global Impression-Bipolar Disorder-Change (CGI-BP-C): Mania</title>
          <description>The CGI-BP-C is a scale which assesses the degree of change or improvement from baseline for each of overall bipolar illness, depression and mania, by grading it using 8 grades, from 1 (very much improved) to 7 (very much worse) or 8 (not applicable). Grade 8 (not applicable) was regarded as a missing value for purposes of calculating the mean score.</description>
          <population>FAS; LOCF imputation method was used for all time points.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="177"/>
                <count group_id="O2" value="74"/>
                <count group_id="O3" value="179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" spread="0.3"/>
                    <measurement group_id="O2" value="4.0" spread="0.2"/>
                    <measurement group_id="O3" value="4.0" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" spread="0.2"/>
                    <measurement group_id="O2" value="4.0" spread="0.2"/>
                    <measurement group_id="O3" value="4.0" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" spread="0.2"/>
                    <measurement group_id="O2" value="4.0" spread="0.2"/>
                    <measurement group_id="O3" value="4.0" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" spread="0.3"/>
                    <measurement group_id="O2" value="4.0" spread="0.4"/>
                    <measurement group_id="O3" value="4.0" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" spread="0.3"/>
                    <measurement group_id="O2" value="3.9" spread="0.2"/>
                    <measurement group_id="O3" value="4.0" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" spread="0.3"/>
                    <measurement group_id="O2" value="3.9" spread="0.3"/>
                    <measurement group_id="O3" value="4.0" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CGI-BP-C: Depression</title>
        <description>The CGI-BP-C is a scale which assesses the degree of change or improvement from baseline for each of overall bipolar illness, depression and mania, by grading it using 8 grades, from 1 (very much improved) to 7 (very much worse) or 8 (not applicable). Grade 8 (not applicable) was regarded as a missing value for purposes of calculating the mean score.</description>
        <time_frame>Weeks 1, 2, 3, 4, 6, 8</time_frame>
        <population>FAS; LOCF imputation method was used for all time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Period I: Placebo</title>
            <description>Participants who received placebo once daily at bedtime for 8 weeks in Treatment Period I.</description>
          </group>
          <group group_id="O2">
            <title>Treatment Period I: FK949E 150 mg</title>
            <description>After 2 days of up-titration, participants received FK949E 150 mg once daily at bedtime for 8 weeks in Treatment Period I.</description>
          </group>
          <group group_id="O3">
            <title>Treatment Period I: FK949E 300 mg</title>
            <description>After 4 days of up-titration, participants received FK949E 300 mg once daily at bedtime for 8 weeks in Treatment Period I.</description>
          </group>
        </group_list>
        <measure>
          <title>CGI-BP-C: Depression</title>
          <description>The CGI-BP-C is a scale which assesses the degree of change or improvement from baseline for each of overall bipolar illness, depression and mania, by grading it using 8 grades, from 1 (very much improved) to 7 (very much worse) or 8 (not applicable). Grade 8 (not applicable) was regarded as a missing value for purposes of calculating the mean score.</description>
          <population>FAS; LOCF imputation method was used for all time points.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="177"/>
                <count group_id="O2" value="74"/>
                <count group_id="O3" value="179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" spread="0.8"/>
                    <measurement group_id="O2" value="3.5" spread="0.8"/>
                    <measurement group_id="O3" value="3.5" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="1.0"/>
                    <measurement group_id="O2" value="3.1" spread="0.9"/>
                    <measurement group_id="O3" value="3.2" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="1.2"/>
                    <measurement group_id="O2" value="2.9" spread="0.9"/>
                    <measurement group_id="O3" value="3.0" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="1.3"/>
                    <measurement group_id="O2" value="2.8" spread="1.0"/>
                    <measurement group_id="O3" value="2.9" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="1.3"/>
                    <measurement group_id="O2" value="2.7" spread="1.0"/>
                    <measurement group_id="O3" value="2.8" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" spread="1.4"/>
                    <measurement group_id="O2" value="2.6" spread="1.1"/>
                    <measurement group_id="O3" value="2.8" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CGI-BP-C: Overall Bipolar Illness</title>
        <description>The CGI-BP-C is a scale which assesses the degree of change or improvement from baseline for each of overall bipolar illness, depression and mania, by grading it using 8 grades, from 1 (very much improved) to 7 (very much worse) or 8 (not applicable). Grade 8 (not applicable) was regarded as a missing value for purposes of calculating the mean score.</description>
        <time_frame>Weeks 1, 2, 3, 4, 6, 8</time_frame>
        <population>FAS; LOCF imputation method was used for all time points.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Period I: Placebo</title>
            <description>Participants who received placebo once daily at bedtime for 8 weeks in Treatment Period I.</description>
          </group>
          <group group_id="O2">
            <title>Treatment Period I: FK949E 150 mg</title>
            <description>After 2 days of up-titration, participants received FK949E 150 mg once daily at bedtime for 8 weeks in Treatment Period I.</description>
          </group>
          <group group_id="O3">
            <title>Treatment Period I: FK949E 300 mg</title>
            <description>After 4 days of up-titration, participants received FK949E 300 mg once daily at bedtime for 8 weeks in Treatment Period I.</description>
          </group>
        </group_list>
        <measure>
          <title>CGI-BP-C: Overall Bipolar Illness</title>
          <description>The CGI-BP-C is a scale which assesses the degree of change or improvement from baseline for each of overall bipolar illness, depression and mania, by grading it using 8 grades, from 1 (very much improved) to 7 (very much worse) or 8 (not applicable). Grade 8 (not applicable) was regarded as a missing value for purposes of calculating the mean score.</description>
          <population>FAS; LOCF imputation method was used for all time points.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="177"/>
                <count group_id="O2" value="74"/>
                <count group_id="O3" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" spread="0.8"/>
                    <measurement group_id="O2" value="3.5" spread="0.8"/>
                    <measurement group_id="O3" value="3.5" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="1.0"/>
                    <measurement group_id="O2" value="3.1" spread="0.9"/>
                    <measurement group_id="O3" value="3.2" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="1.2"/>
                    <measurement group_id="O2" value="2.9" spread="0.9"/>
                    <measurement group_id="O3" value="3.0" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="1.3"/>
                    <measurement group_id="O2" value="2.8" spread="1.0"/>
                    <measurement group_id="O3" value="2.9" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="1.4"/>
                    <measurement group_id="O2" value="2.7" spread="1.0"/>
                    <measurement group_id="O3" value="2.9" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" spread="1.5"/>
                    <measurement group_id="O2" value="2.6" spread="1.1"/>
                    <measurement group_id="O3" value="2.8" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events</title>
        <description>An adverse event (AE) is defined as any undesirable or unintended sign (including abnormal laboratory test values), symptom, or disease occurring while the study drug was administered, regardless of whether or not there was a causal relationship with the study drug. A serious AE is defined as a an event resulting in death, persistent or significant disability/incapacity or congenital anomaly or birth defect, was life-threatening, required or prolonged hospitalization or was considered medically important.</description>
        <time_frame>up to 8 weeks</time_frame>
        <population>Safety Analysis Set (SAF), which included participants who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Period I: Placebo</title>
            <description>Participants who received placebo once daily at bedtime for 8 weeks in Treatment Period I.</description>
          </group>
          <group group_id="O2">
            <title>Treatment Period I: FK949E 150 mg</title>
            <description>After 2 days of up-titration, participants received FK949E 150 mg once daily at bedtime for 8 weeks in Treatment Period I.</description>
          </group>
          <group group_id="O3">
            <title>Treatment Period I: FK949E 300 mg</title>
            <description>After 4 days of up-titration, participants received FK949E 300 mg once daily at bedtime for 8 weeks in Treatment Period I.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <description>An adverse event (AE) is defined as any undesirable or unintended sign (including abnormal laboratory test values), symptom, or disease occurring while the study drug was administered, regardless of whether or not there was a causal relationship with the study drug. A serious AE is defined as a an event resulting in death, persistent or significant disability/incapacity or congenital anomaly or birth defect, was life-threatening, required or prolonged hospitalization or was considered medically important.</description>
          <population>Safety Analysis Set (SAF), which included participants who received at least one dose of study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="177"/>
                <count group_id="O2" value="74"/>
                <count group_id="O3" value="179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                    <measurement group_id="O2" value="55"/>
                    <measurement group_id="O3" value="149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drug-related AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="50"/>
                    <measurement group_id="O3" value="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drug-related SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs that caused study drug discontimuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drug-related AEs that caused study drug discont.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Drug Induced Extra-Pyramidal Symptoms Scale (DIEPSS): Total Score</title>
        <description>The DIEPSS is a scale used to evaluate drug-induced extrapyramidal symptoms. DIEPSS is composed of 8 individual symptom parameters and a global assessment of severity, each rated on a 5-point scale, with lower scores indicating as &quot;normal.&quot; The DIEPSS total score ranges from 0 (none, normal) to 32 (severe), and excludes the global assessment of severity.</description>
        <time_frame>Baseline and Weeks 4, 8</time_frame>
        <population>SAF; LOCF imputation method for end of Treatment period I was used. N is the number of participants with available data at the time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Period I: Placebo</title>
            <description>Participants who received placebo once daily at bedtime for 8 weeks in Treatment Period I.</description>
          </group>
          <group group_id="O2">
            <title>Treatment Period I: FK949E 150 mg</title>
            <description>After 2 days of up-titration, participants received FK949E 150 mg once daily at bedtime for 8 weeks in Treatment Period I.</description>
          </group>
          <group group_id="O3">
            <title>Treatment Period I: FK949E 300 mg</title>
            <description>After 4 days of up-titration, participants received FK949E 300 mg once daily at bedtime for 8 weeks in Treatment Period I.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Drug Induced Extra-Pyramidal Symptoms Scale (DIEPSS): Total Score</title>
          <description>The DIEPSS is a scale used to evaluate drug-induced extrapyramidal symptoms. DIEPSS is composed of 8 individual symptom parameters and a global assessment of severity, each rated on a 5-point scale, with lower scores indicating as &quot;normal.&quot; The DIEPSS total score ranges from 0 (none, normal) to 32 (severe), and excludes the global assessment of severity.</description>
          <population>SAF; LOCF imputation method for end of Treatment period I was used. N is the number of participants with available data at the time point.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="177"/>
                <count group_id="O2" value="74"/>
                <count group_id="O3" value="179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4 [N=160, 68, 159]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.5"/>
                    <measurement group_id="O2" value="0.0" spread="0.7"/>
                    <measurement group_id="O3" value="0.2" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 [N=136, 60, 140]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.5"/>
                    <measurement group_id="O2" value="0.0" spread="0.7"/>
                    <measurement group_id="O3" value="0.1" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Treatment Period I [N=173, 73, 176]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.6"/>
                    <measurement group_id="O2" value="0.0" spread="0.8"/>
                    <measurement group_id="O3" value="0.1" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in DIEPSS: Parkinsonism</title>
        <description>The DIEPSS is a scale used to evaluate drug-induced extrapyramidal symptoms. DIEPSS is composed of 8 individual symptom parameters and a global assessment of severity, each rated on a 5-point scale, with lower scores indicating as &quot;normal.&quot; Parkinsonism is a total of the gait disturbance, bradykinesia, salivation, muscle rigidity, and tremor scores and ranges from 0 (none, normal) to 20 (severe).</description>
        <time_frame>Baseline and Weeks 4, 8</time_frame>
        <population>SAF; LOCF imputation method for end of Treatment period I was used. N is the number of participants with available data at the time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Period I: Placebo</title>
            <description>Participants who received placebo once daily at bedtime for 8 weeks in Treatment Period I.</description>
          </group>
          <group group_id="O2">
            <title>Treatment Period I: FK949E 150 mg</title>
            <description>After 2 days of up-titration, participants received FK949E 150 mg once daily at bedtime for 8 weeks in Treatment Period I.</description>
          </group>
          <group group_id="O3">
            <title>Treatment Period I: FK949E 300 mg</title>
            <description>After 4 days of up-titration, participants received FK949E 300 mg once daily at bedtime for 8 weeks in Treatment Period I.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in DIEPSS: Parkinsonism</title>
          <description>The DIEPSS is a scale used to evaluate drug-induced extrapyramidal symptoms. DIEPSS is composed of 8 individual symptom parameters and a global assessment of severity, each rated on a 5-point scale, with lower scores indicating as &quot;normal.&quot; Parkinsonism is a total of the gait disturbance, bradykinesia, salivation, muscle rigidity, and tremor scores and ranges from 0 (none, normal) to 20 (severe).</description>
          <population>SAF; LOCF imputation method for end of Treatment period I was used. N is the number of participants with available data at the time point.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="177"/>
                <count group_id="O2" value="74"/>
                <count group_id="O3" value="179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4 [N=160, 68, 159]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.4"/>
                    <measurement group_id="O2" value="-0.1" spread="0.5"/>
                    <measurement group_id="O3" value="0.0" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 [N=136, 60, 140]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.3"/>
                    <measurement group_id="O2" value="-0.1" spread="0.5"/>
                    <measurement group_id="O3" value="-0.1" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment Period I [N=173, 73, 176]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.4"/>
                    <measurement group_id="O2" value="-0.1" spread="0.5"/>
                    <measurement group_id="O3" value="-0.1" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Young Mania Rating Scale (YMRS)</title>
        <description>The YMRS is a scale used to evaluate manic symptoms. The YMRS total score was the total assessment of assessed points for 11 items, ranges from 0 to 60 (each item is scored from either 0-4 or 0-8 by severity (0 = absent and 4/8 = displays mood/behavior to a greater degree). A lower score indicates “Absent” or “Normal.&quot;</description>
        <time_frame>Baseline and Weeks 1, 2, 3 4, 6, 8</time_frame>
        <population>SAF; LOCF imputation method for end of Treatment period I was used. N is the number of participants with available data at the time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Period I: Placebo</title>
            <description>Participants who received placebo once daily at bedtime for 8 weeks in Treatment Period I.</description>
          </group>
          <group group_id="O2">
            <title>Treatment Period I: FK949E 150 mg</title>
            <description>After 2 days of up-titration, participants received FK949E 150 mg once daily at bedtime for 8 weeks in Treatment Period I.</description>
          </group>
          <group group_id="O3">
            <title>Treatment Period I: FK949E 300 mg</title>
            <description>After 4 days of up-titration, participants received FK949E 300 mg once daily at bedtime for 8 weeks in Treatment Period I.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Young Mania Rating Scale (YMRS)</title>
          <description>The YMRS is a scale used to evaluate manic symptoms. The YMRS total score was the total assessment of assessed points for 11 items, ranges from 0 to 60 (each item is scored from either 0-4 or 0-8 by severity (0 = absent and 4/8 = displays mood/behavior to a greater degree). A lower score indicates “Absent” or “Normal.&quot;</description>
          <population>SAF; LOCF imputation method for end of Treatment period I was used. N is the number of participants with available data at the time point.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="177"/>
                <count group_id="O2" value="74"/>
                <count group_id="O3" value="179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1 [N=177, 74, 179]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="1.6"/>
                    <measurement group_id="O2" value="-0.6" spread="1.8"/>
                    <measurement group_id="O3" value="-0.6" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 [N=165, 72, 162]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="1.4"/>
                    <measurement group_id="O2" value="-1.0" spread="1.5"/>
                    <measurement group_id="O3" value="-0.7" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3 [N=158, 67, 157]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="1.9"/>
                    <measurement group_id="O2" value="-1.2" spread="1.7"/>
                    <measurement group_id="O3" value="-0.7" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 [N=146, 66, 150]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="1.7"/>
                    <measurement group_id="O2" value="-1.3" spread="2.0"/>
                    <measurement group_id="O3" value="-0.9" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 [N=144, 62, 147]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="2.2"/>
                    <measurement group_id="O2" value="-1.4" spread="2.1"/>
                    <measurement group_id="O3" value="-0.8" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 [N=135, 59, 138]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="1.6"/>
                    <measurement group_id="O2" value="-1.7" spread="2.3"/>
                    <measurement group_id="O3" value="-0.9" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Treatment Period 1 [N=177, 74, 179]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="2.1"/>
                    <measurement group_id="O2" value="-1.6" spread="2.3"/>
                    <measurement group_id="O3" value="-0.8" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With an Affirmative Response to Columbia Suicide Severity Rating Scale (C-SSRS): Suicidal Ideation</title>
        <description>The C-SSRS is a scale for assessing risk for suicidal behavior and suicide ideation and was administered by the clinician. Affirmative or negative responses were provided to 5 items for suicide ideation (1. Wish to be dead; 2. Suicidal thoughts; 3. Suicidal thoughts with a method (no specific plan or intent to act); 4. Suicidal intent (without a specific plan); 5. Suicidal intent with specific plan. If participants responded with a negative response for questions 1 and 2, the remaining questions are skipped. If question 2 was responded to with a positive response, the remaining questions need to be asked.</description>
        <time_frame>Weeks 4, 8</time_frame>
        <population>SAF; LOCF imputation method was used for all time points. N is the number of participants with available data. Only participants who had a response were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Period I: Placebo</title>
            <description>Participants who received placebo once daily at bedtime for 8 weeks in Treatment Period I.</description>
          </group>
          <group group_id="O2">
            <title>Treatment Period I: FK949E 150 mg</title>
            <description>After 2 days of up-titration, participants received FK949E 150 mg once daily at bedtime for 8 weeks in Treatment Period I.</description>
          </group>
          <group group_id="O3">
            <title>Treatment Period I: FK949E 300 mg</title>
            <description>After 4 days of up-titration, participants received FK949E 300 mg once daily at bedtime for 8 weeks in Treatment Period I.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With an Affirmative Response to Columbia Suicide Severity Rating Scale (C-SSRS): Suicidal Ideation</title>
          <description>The C-SSRS is a scale for assessing risk for suicidal behavior and suicide ideation and was administered by the clinician. Affirmative or negative responses were provided to 5 items for suicide ideation (1. Wish to be dead; 2. Suicidal thoughts; 3. Suicidal thoughts with a method (no specific plan or intent to act); 4. Suicidal intent (without a specific plan); 5. Suicidal intent with specific plan. If participants responded with a negative response for questions 1 and 2, the remaining questions are skipped. If question 2 was responded to with a positive response, the remaining questions need to be asked.</description>
          <population>SAF; LOCF imputation method was used for all time points. N is the number of participants with available data. Only participants who had a response were included in the analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="173"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4: Wish to be dead [N=160, 68, 159]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Suicidal thoughts [N=160, 68, 159]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Suicidal thoughts w/ method [N=11, 3, 12]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Suicidal intent (w/o plan) [N=11, 3, 12]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Suicidal intent w/ plan [N=11, 3, 12]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Wish to be dead [N=173, 73, 176]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Suicidal thoughts [N=173, 73, 176]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Suicidal thoughts w/ method [N=16, 3, 16]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Suicidal intent (w/o plan) [N=16, 3, 16]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Suicidal intent w/ plan [N=16, 3, 16]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With an Affirmative Response to C-SSRS: Suicidal Behaviors</title>
        <description>The C-SSRS is a scale for assessing risk for suicidal behavior and suicide ideation and was administered by the clinician. Affirmative or negative responses were provided to 7 items to suicidal behaviors (1. suicide attempt; 2. Self-injury without suicide intent; 3. discontinued suicide attempt; 4. interrupted suicide attempt; 5. preliminary action to suicide; 6. suicidal behavior; 7. completed suicide).</description>
        <time_frame>Weeks 4, 8</time_frame>
        <population>SAF; LOCF imputation method was used for all time points. N is the number of participants with available data. Only participants who had a response were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Period I: Placebo</title>
            <description>Participants who received placebo once daily at bedtime for 8 weeks in Treatment Period I.</description>
          </group>
          <group group_id="O2">
            <title>Treatment Period I: FK949E 150 mg</title>
            <description>After 2 days of up-titration, participants received FK949E 150 mg once daily at bedtime for 8 weeks in Treatment Period I.</description>
          </group>
          <group group_id="O3">
            <title>Treatment Period I: FK949E 300 mg</title>
            <description>After 4 days of up-titration, participants received FK949E 300 mg once daily at bedtime for 8 weeks in Treatment Period I.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With an Affirmative Response to C-SSRS: Suicidal Behaviors</title>
          <description>The C-SSRS is a scale for assessing risk for suicidal behavior and suicide ideation and was administered by the clinician. Affirmative or negative responses were provided to 7 items to suicidal behaviors (1. suicide attempt; 2. Self-injury without suicide intent; 3. discontinued suicide attempt; 4. interrupted suicide attempt; 5. preliminary action to suicide; 6. suicidal behavior; 7. completed suicide).</description>
          <population>SAF; LOCF imputation method was used for all time points. N is the number of participants with available data. Only participants who had a response were included in the analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="173"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4: Suicide attempt [N=160, 68, 159]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Self-injury w/o intent [N=160, 68, 159]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Discontinued attempt [N=160, 68, 159]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Interrupted attempt [N=160, 68, 159]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Preliminary act to suicide [N=160,68,159]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Suicidal behavior [N=160, 68, 159]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Completed suicide [N=160, 68, 159]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Suicide attempt [N=173, 73, 176]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Self-injury w/o intent [N=173, 73, 176]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Discontinued attempt [N=173, 73, 176]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Interrupted attempt [N=173, 73, 176]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Preliminary act to suicide [N=173,73,176]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Suicidal behavior [N=173, 73, 176]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Completed suicide [N=173, 73, 176]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 8 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment Period I: Placebo</title>
          <description>Participants who received placebo once daily at bedtime for 8 weeks in Treatment Period I.</description>
        </group>
        <group group_id="E2">
          <title>Treatment Period I: FK949E 150 mg</title>
          <description>After 2 days of up-titration, participants received FK949E 150 mg once daily at bedtime for 8 weeks in Treatment Period I.</description>
        </group>
        <group group_id="E3">
          <title>Treatment Period I: FK949E 300 mg</title>
          <description>After 4 days of up-titration, participants received FK949E 300 mg once daily at bedtime for 8 weeks in Treatment Period I.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.0</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Successful suicide</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 18.0</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="138" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperprolactinemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Xerostomia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Dipsia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="50" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Sprained ligament</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Increased alanine aminotransferase</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Increased aspartate aminotransferase</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Increased blood creatine phosphokinase</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Increased blood prolactin</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Increased blood triglycerides</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Akathisia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Postural dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="80" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Hypomania</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript prior to publication for review and comment.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Head of Clinical Development Administration</name_or_title>
      <organization>Astellas Pharma Inc.</organization>
      <email>Astellas.resultsdisclosure@astellas.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
